Low rates of diabetic patients reaching good control targets;Faibles taux de patients diabétiques atteignant de bons objectifs de contrôle

Eastern Mediterranean Health Journal

Volumn 7, Issue 4-5, 2001, Pages 671-678

  Akbar, D H ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPID; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIABETES CONTROL; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PREVALENCE; UNIVERSITY HOSPITAL; AGED; BLOOD; DEMOGRAPHY; DIABETES MELLITUS; METABOLISM; NEEDS ASSESSMENT; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; RISK FACTOR; SAUDI ARABIA; SEX DIFFERENCE; STATISTICS; TIME;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALS, UNIVERSITY; HUMANS; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NEEDS ASSESSMENT; OUTPATIENT CLINICS, HOSPITAL; PATIENT COMPLIANCE; RESIDENCE CHARACTERISTICS; RISK FACTORS; SAUDI ARABIA; SEX FACTORS; TIME FACTORS;

EID: 4944242859     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications. eslirridles and projections to the year 2010. Diabetic medicine, 1997, 14(suppl 5):S1-8.
2. Zimmet PZ. Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia, 1999, 42:499-518.
3. Garcia MJ et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up. Diabetes, 1974, 23:105-11.
4. Stamler J et al. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes care, 1993, 16:434-44.
5. Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) Study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. American heart journal, 1988, 116:1713-24.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet, 1998, 352:837-53.
7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. (UKPDS 39). British medical journal, 1998, 317: 703-13.
8. Pyorala K et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes care, 1997, 20:614-20.
9. Goldberg RB et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intoler-anl myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) Trial. Circulation, 1998, 98:2513-9.
10. The Long-Term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England journal of medicine, 1998, 339:1349-57.
11. The health benefits of smoking cessation. A report of the Surgeon General. Atlanta, GA, Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 1990.
12. Serrano Rios M. Relationship between obesity and the increased risk of major complications in non-insulin dependent diabetes mellitus. European journal of clinical investigations, 1998, 28(suppl 12): 14-8.
13. Diabetes mellitus: report of a WHO Study Group. Geneva, World Health Organization, 1985:1 113 (WHO Technical Report Series No. 727).
14. American Diabetes Association Clinical Practice Recommendations 2000. Diabetes care, 2000, 23 (suppl):S1-116.
15. Wingard DL, Barrett-Connor E. Heart disease and diabetes, In: Diabetes in America, 2nd ed. Bethesda, MD, National Diabetes Data Group, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995:429-48 (NIH Publication No. 95-1468).
16. Haffner SM et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England journal of medicine, 1998, 339:229-34.
17. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: National Diabetes Data Group. Diabetes in America. 2nd ed. Washington, DC, Govt, printing office, 1995:233-58.
18. Lehto S et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes, 1997, 46:1354-9.
19. The National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension, 1994, 23:145-58.
20. Akbar DH. Is hypertension is common in hospitalized type 2 diabetic patients. Saudi medical journal, 2001, 22(2): 139-41.
21. Hypertension in Diabetes Study (HDS). I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. Journal of hypertension, 1993, 11:309-25.
22. Wokoma FS. Hypertension in non-insulin dependent diabetic Nigerians: a comparative analysis of normotensive and hypertensive subgroups. Diabetes international, 1999, 9(3):57-8.
23. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet, 1998, 351:755-62.
24. Wright-Pascoe R, Lindo JF. The age-prevalence profile of abdominal obesity among patients in a diabetic referral clinic in Jamaica. West Indian medical journal, 1997, 46(3):72-5.
25. El-Hazmi MA, Warsy AS. Obesity and overweight in type-2 diabetes mellitus patients in Saudi Arabia. Saudi medical journal, 1999, 20(2):167-71.
26. Turki YA. Obesity among diabetic patients in a primary health care center. Saudi medical journal, 1999. 20(10): 763-65.
27. Bo S, Cavallo-Perin P, Gentile L. Prevalence of patients reaching the targets of good control in normal clinical practice. Diabetes care, 1999, 22(12):2092
28. Siribaddana S et al. Prevalence of lipid abnormalities in Sri Lankan patients with non-insulin dependent diabetes mellitus. A cohort-based study in type 2 diabetes. Ceylon medical journal, 1994, 39(1):22-5.
29. Loh KC et al. I ligh prevalence of dyslipidemia despite adequate glycae-mic control in patients with diabetes. Annals of the Academy of Medicine, Singapore, 1996, 25(2):228-32.
30. Akbar DH. Role of hyperlipidemia in diabetic patients. Diabetes international, 2000, 11:17-8.
31. Stevenson FT, Kaysen GA. Hyperlipi-dernia and renal disease: the use of animal models in understanding pathophysiology and approaches to treatment. Wiener klinische Wochonschrift, 1999, 111 (8):307-14.
32. Phillips A, Janssen U, Floege J. Progression of diabetic nephropathy. Insight from cell culture studies and animal models. Kidney and blood pressure research, 1999, 22(1-2):81-97.
33. Sjoholm A. Dags for aktivarc lipidsan-kande behandling av diabetiker. Negativa effekter av hyperlipidemi pa betaceller har varit forsummat omrade. [Time for more active lipid-lowering treatment of patients with diabetes. Negative effect of hyperlipidemia on beta-cells is a neglected field.] Lakartid-ningen, 1998, 95(50):5750-2.
34. Tonolo G et al. Reduction of albumin excretion rate in normotensive microalbu-minuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes care, 1997, 20(17): 1891-5.
35. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England journal of medicine, 1993, 329:977-86.